The Debio 1454M program includes novel microbiome therapeutics for the treatment of gastrointestinal (GI) disorders. Currently in drug candidate identification stage, the program aims to identify effective treatment against inflammatory bowel disease (IBD) and other GI disorders. The preclinical program is focused on novel, narrow spectrum, microbiome remodeling agents targeting a combination of intestinal pathobiont bacterial species. Drug candidates will be evaluated for their effectiveness against specific disease-causing microorganisms while preserving the natural balance of the microbiota.
June 10, 2020
Debiopharm’s novel microbiome remodeling program licensed to Takeda for the treatment of gastrointestinal disorders